Skip to main content

Table 3 Univariate associations between baseline demographics and interval durationsa

From: The time required to diagnose and treat lung cancer in Delhi, India: an updated experience of a public referral center

  Evaluation durations Treatment duration Total duration
Symptom onset to definitive diagnostic study Diagnostic study to confirmed diagnosis Confirmed diagnosis to chemotherapy initiation Symptom onset to chemotherapy initiation
Age
  < 60 years 105 [61–170.8]   6 [3–8]   19 [11–31]   127 [85.5–211]  
  > 60 years 99 [53–167] p = 0.312 6 [4–9] p = 0.445 21 [13–34.8] p = 0.081 125 [84–182] p = 0.278
Sex
 Male 101 [55.8–170]   5 [3–8]   20 [11–32]   126 [84–194]  
 Female 100 [55–166.5] p = 0.644 6 [4–8.3] p = 0.101 21.5 [11.3–36.8] p = 0.516 127 [86–212.5] p = 0.475
Living
 Within Delhi Region 107.5 [61–171]   5 [4–9]   19 [11–32]   130.5 [87–201]  
 Outside Delhi 92.5 [52–167] p = 0.332 6 [3–8] p = 0.998 21 [11–34] p = 0.643 125 [83.5–197.5] p = 0.482
Income
 Above Poverty Lineb 99 [62–169]   6 [3–9]   21 [12–36]   131.5 [90–192]  
 Below Poverty Line 97.5 [54.8–166.3] p = 0.860 5 [3–7.3] p = 0.091 16 [8.3–25.8] p = 0.034 113 [68–216] p = 0.247
Education
 Primary education or less 104 [64.5–171]   6 [3–9]   19 [11–35]   127 [83–215.5]  
 Some High School or More 99 [52.8–173] p = 0.521 5 [3–8] p = 0.254 21 [12–31.3] p = 0.851 127 [84.8–205.8] p = 0.617
Smoking Status
 Never Smoker 107.5 [57.8–172.5]   6 [3–8]   21 [10–32.5]   136 [88.5–212.5]  
 Current Smoker 91 [48.5–166.5]   6 [3–9]   19 [11–32]   122 [72.5–186]  
 Previously Quit 108 [62–171] p = 0.131 5 [3.8–8] p = 0.729 22 [12–35] p = 0.462 126 [90–188.3] p = 0.140
ECOG Performance Status
 0 or 1 93 [51–167]   5 [3–8]   23 [13–35]   125 [90–195]  
 2 or 3 99 [59.5–165.5]   6 [4–10]   19 [11–34]   126 [79.3–186]  
 4 or 5 148 [90.5–199.3] p = 0.275 4 [2.5–8.5] p = 0.015 21.5 [15.8–67] p = 0.140 156 [86.8–216.3] p = 0.875
KPS Score
 KPS >/ 70 98.5 [52.8–168]   6 [3–8]   21 [12–33]   125 [84–193]  
 KPS < 70 106 [70.3–170.3] p = 0.291 6 [4–9] p = 0.149 21 [12–40] p = 0.628 127 [90–213.5] p = 0.227
Previous ATT History
 Did not receive ATT 83 [50–159]   5 [3–8]   19 [11–31]   113 [75–180]  
 Received ATT 150 [93–216] p < .0001 5 [3–8] p < 0.997 22 [11.5–36] p = 0.093 187 [134–261.5] p < .0001
Type of Definitive Biopsy
 Bronchoscopy 101 [53–167]   6 [4–9]   20 [12–32]   126 [80.5–195.8]  
 CT-Guided Lung Biopsy 107 [72–171]   6 [4–8]   22 [12.5–42.5]   150 [96.3–227.3]  
 US-Guided Lung Biopsy 83.5 [46.3–166]   6 [4–8]   20.5 [4.8–33.8]   90 [60–180]  
 Thorascopy 75 [49–140]   5 [4–7]   22 [8–34]   103.5 [60–205]  
 Surgical 83 [1 patient]   13 [1–26]   16 [1 patient]   N/A  
 Other 88 [51–171] p = 0.259 2 [1–6] p = .0001 21 [9.5–30.5] p = 0.480 124.5 [90–194] p = 0.090
Histologic Diagnosis
 NSCLC 108 [65–172]   5 [3–8]   22 [12–35]   133 [90–210.5]  
 SCLC 75 [42–122] p < .0001 7 [4–10] p < .0001 15 [9–23] p < .0001 94.5 [65–157.3] p < .0001
NSCLC Stage at Diagnosis
 Stage 1 90 [70.8–328.3]   5 [4–9]   63 [1 patient]   151 [1 patient]  
 Stage 2 104.5 [74–172.3]   6 [3–7]   51 [23.5–86.5]   163 [132–261.5]  
 Stage 3 109 [66–172]   5 [3–8]   21 [15–34]   157 [103–216]  
 Stage 4 90.5 [53.8–167] p = 0.151 5 [3–8] p = 0.942 22 [11–34] p = 0.027 126 [87–207.8] p = 0.159
SCLC Stage at Diagnosis
 Limited 74.5 [45.3–132.5]   8 [5–12]   16 [7.5–25]   98 [73–163.5]  
 Extensive 75 [41.3–124.8] p = 0.616 7 [4–10] p = 0.158 15 [9–23] p = 0.944 98 [65–156] p = 0.546
  1. ECOG Eastern cooperative oncology group, KPS Karnofsky performance status, ATT Anti-tuberculosis treatment, NSCLC non-small cell lung cancer, SCLC small cell lung cancer
  2. aAll durations were expressed as median days with inter-quartile range
  3. bThe poverty line defined by the World Bank is $1.90 US daily per capita